Get the Stockscreener App
10.08
4.00%
-0.42
After Hours:
10.08
Entrada Therapeutics Inc stock is traded at $10.08, with a volume of 238.15K.
It is down -4.00% in the last 24 hours and down -2.33% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$10.50
Open:
$10.49
24h Volume:
238.15K
Relative Volume:
1.11
Market Cap:
$385.25M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
3.4054
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
-0.10%
1M Performance:
-2.33%
6M Performance:
+39.42%
1Y Performance:
-44.16%
1-Day Range:
$9.87
$10.63
1-Week Range:
$9.84
$10.63
52-Week Range:
$4.93
$18.42
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
10.08 | 401.30M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
Price-Driven Insight from (TRDA) for Rule-Based Strategy - Stock Traders Daily
Vesuvius India Limited Moves Into Overbought Range Analysts CautiousSell Signals and Alerts & Double Or Triple Wealth - bollywoodhelpline.com
Entrada Therapeutics Inc (TRDA) Stock News & Articles - 24/7 Wall St.
AVP Infracon Limited Breaks Below Key Support LevelGlobal Trade Effects & Affordable Trading Strategies - Bollywood Helpline
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion - MSN
Analyst Downgrade: Will Entrada Therapeutics Inc stock return to pre crisis levels2025 Market Overview & Verified Entry Point Detection - moha.gov.vn
Tubes Limited Inches Toward Key Resistance — Will It BreakRisk Adjusted Returns & Low Risk Trading Ideas - Bollywood Helpline
Beeyu Overseas Limited Included in Top Momentum ScanVolume Profile Analysis & Big Data Market Reports - Bollywood Helpline
Option Seller’s Risk Unlimited (in theory)REITs Market Trends & Big Gains Small Capital - bollywoodhelpline.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics Earnings Notes - Trefis
Is Entrada Therapeutics Inc. stock vulnerable to regulatory risksChart Signals & Weekly Momentum Picks - Улправда
How Entrada Therapeutics Inc. stock compares to industry benchmarksDay Trade & Safe Capital Allocation Plans - Улправда
Is Entrada Therapeutics Inc. stock positioned for long term growth2025 Volume Leaders & Fast Momentum Stock Entry Tips - Улправда
Is Entrada Therapeutics Inc. stock safe for conservative investors2025 Big Picture & Verified Trade Idea Suggestions - Улправда
How Entrada Therapeutics Inc. stock reacts to job market dataWeekly Trade Review & Risk Controlled Swing Alerts - Улправда
How resilient is Entrada Therapeutics Inc. stock in market downturnsJuly 2025 Snapshot & Weekly High Return Stock Forecasts - DonanımHaber
What insider trading reveals about Entrada Therapeutics Inc. stockQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Bölüm Sonu Canavarı
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Will Entrada Therapeutics Inc. stock benefit from commodity pricesWeekly Trading Summary & Verified Technical Signals - DonanımHaber
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Entrada Therapeutics : Corporate Presentation December 2025 - marketscreener.com
5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA - MarketBeat
Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily
Entrada Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Reports Third Quarter 2025 Financial Results - ADVFN
Brokerages Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) Price Target at $20.67 - Defense World
Baker Bros. Advisors LP Increases Stake in Entrada Therapeutics Inc. - GuruFocus
Major Investment Alert: Baker Bros. Advisors Boosts Stake in Entrada Therapeutics! - TipRanks
Kory James Wentworth Sells 8,910 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Insider Sell: Kory Wentworth Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus
Entrada Therapeutics CFO Sells Shares Under Trading Plan - TradingView
CFO Wentworth Sells 8,910 ($88.9K) Of Entrada Therapeutics Inc [TRDA] - TradingView
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
CFO Wentworth Files To Sell 8,910 Of Entrada Therapeutics Inc [TRDA] - TradingView
Will Entrada Therapeutics Inc. stock deliver shareholder valueWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Entrada Therapeutics (TRDA) Price Target Decreased by 10.81% to 16.83 - MSN
Why Entrada Therapeutics Inc. stock is favored by pension fundsTrade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
(TRDA) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Questex’s Fierce Life Sciences Announces 2025 Innovation Awards Winners - GlobeNewswire Inc.
How risky is Entrada Therapeutics Inc. stock now2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells 200,000 Shares of Stock - MarketBeat
Can Entrada Therapeutics Inc. stock resist market sell offs2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Major Stock Sell-Offs at Entrada Therapeutics Inc! - TipRanks
Applying big data sentiment scoring on Entrada Therapeutics Inc.2025 Top Decliners & Consistent Return Investment Signals - newser.com
Owner 5AM Ventures V LP Sells 200,000 ($1.8M) Of Entrada Therapeutics Inc [TRDA] - TradingView
Chmn Parmar Sells 200,000 ($1.8M) Of Entrada Therapeutics Inc [TRDA] - TradingView
Is Entrada Therapeutics Inc a good long term investmentEarnings Growth Projections & Real-Life Case Studies You Can Follow - earlytimes.in
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entrada Therapeutics Inc Stock (TRDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 10% Owner |
Nov 20 '25 |
Buy |
9.07 |
28,867 |
261,846 |
4,691,392 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):